Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | FGFR3 | P22607 | 6/20 | 0.43 |
| ▸ | CALM1 | P0DP23 | 3/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 6/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23060197 | 0.90 | CYP19A1 (0.43) | CYP19A1FGFR3CALM1AKR1B1FGFR1 | |
| SCHEMBL3936196 | 0.86 | TAAR1 (0.47) | CYP19A1CALM1DAOALDH1A1DHFR | |
| SCHEMBL63824 | 0.85 | TAAR1 (0.54) | DAODHFR | |
| SCHEMBL4010043 | 0.82 | FGFR1 (0.47) | CYP19A1FGFR3FGFR1ALDH1A1HPGD | |
| SCHEMBL19848825 | 0.78 | FGFR1 (0.43) | CYP19A1FGFR3CALM1AKR1B1FGFR1 | |
| SCHEMBL16234207 | 0.76 | AKR1B1 (0.48) | CYP19A1FGFR3CALM1AKR1B1FGFR1 | |
| SCHEMBL63314 | 0.75 | ADRA1A (0.55) | ALDH1A1HSD17B10DHFR | |
| SCHEMBL64323 | 0.75 | KMT2A (0.49) | ALDH1A1HPGD | |
| SCHEMBL1922681 | 0.74 | CYP19A1 (0.51) | CYP19A1FGFR3FGFR1KDRDAO | |
| SCHEMBL22636476 | 0.74 | ALDH1A1 (0.47) | ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114728910-B | Pyrazole derivative for FGFR inhibitor and preparation method thereof | 上海奕拓医药科技有限责任公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-115819239-A | Intermediate of fibroblast growth factor receptor inhibitor and preparation method and application thereof | 无锡和誉生物医药科技有限公司 | 2023-03-21 | — | — | CN | disclosed |
| US-20220298143-A1 | Pyrazole Derivatives for FGFR Inhibitor and Preparation Method Thereof | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2022-09-22 | — | — | US | disclosed |
| CN-114728910-A | Pyrazole derivatives for FGFR inhibitor and preparation method thereof | 上海奕拓医药科技有限责任公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-4023639-A1 | PYRAZOLE DERIVATIVE FOR FGFR INHIBITOR AND PREPARATION METHOD THEREFOR | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2022-07-06 | — | — | EP | disclosed |
| EP-4023639-A1 | PYRAZOLE DERIVATIVE FOR FGFR INHIBITOR AND PREPARATION METHOD THEREFOR | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2022-07-06 | — | — | EP | disclosed |
| CN-112441980-A | Pyrazole derivatives for FGFR inhibitor and preparation method thereof | 上海奕拓医药科技有限责任公司 | 2021-03-05 | — | — | CN | disclosed |
| WO-2021037219-A1 | PYRAZOLE DERIVATIVE FOR FGFR INHIBITOR AND PREPARATION METHOD THEREFOR | 上海奕拓医药科技有限责任公司 | 2021-03-04 | — | — | WO | disclosed |
| WO-2021037219-A1 | PYRAZOLE DERIVATIVE FOR FGFR INHIBITOR AND PREPARATION METHOD THEREFOR | 上海奕拓医药科技有限责任公司 | 2021-03-04 | — | — | WO | disclosed |
| CN-111936470-A | Amidopyrazoles useful as FGFR irreversible inhibitors | 中国科学院上海有机化学研究所 | 2020-11-13 | — | — | CN | disclosed |
| WO-2009153592-A1 | PYRAZOLE COMPOUNDS 436 | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009153592-A1 | PYRAZOLE COMPOUNDS 436 | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | WO | disclosed |
| EP-2125748-A2 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | AstraZeneca AB (SE) | 2009-12-02 | — | — | EP | disclosed |
| WO-2009056886-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF FGFR ACTIVITY | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | WO | disclosed |
| EP-2044063-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2009019518-A1 | PYRIMIDINE COMPOUNDS HAVING A FGFR INHIBITORY EFFECT | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | WO | disclosed |
| WO-2008075068-A2 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | HDAC1, HDAC11, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CYP19A1 241/4885FGFR3 773/4885CALM1 1644/4885 |
| US-20220298143-A1 | Pyrazole Derivatives for FGFR Inhibitor and Preparation Method Thereof | FGFR1, FGFR2, FGFR3 | CYP19A1 101/4885FGFR3 3/4885CALM1 2088/4885 |
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | CYP19A1 87/4885FGFR3 2897/4885CALM1 3653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.